| Company Name: |
Shanghai YuanYe Biotechnology Co., Ltd.
|
| Tel: |
021-61312847; 18021002903 |
| Email: |
3008007409@qq.com |
| Products Intro: |
Product Name:Tucotuzumab (anti-EpCAM)
CAS:339986-90-2
Purity:Carrier Free, 重组, ExactAb?, Low Endotoxin, Azide Free, Valid Package:100μg Remarks:K14478
|
| Company Name: |
Shanghai Han-Xiang Chemical Co., Ltd.
|
| Tel: |
15971444841 17754423994 |
| Email: |
candy@biochempartner.com |
| Products Intro: |
Product Name:Tucotuzumab Celmoleukin
CAS:339986-90-2
Purity:98% HPLC LCMS Package:100ug;1mg
|
| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Tucotuzumab Celmoleukin
Purity:>95%;1mg/ml Package:200ug;500ug;1mg
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Products Intro: |
Product Name:Research Grade Tucotuzumab (DHD17404)
CAS:339986-90-2
Purity:PAGE:>95% Package:100ug;1mg
|
| Company Name: |
Wuhan Jingkangen Biomedical Technology Co., Ltd
|
| Tel: |
13720134139 086-15871494362 13720134139 |
| Email: |
orders@jknbiochem.com |
| Products Intro: |
Product Name:Tucotuzumab Celmoleukin
CAS:339986-90-2
Purity:95% Package:100ug:500ug:1mg
|
|
| | Tucotuzumab Celmoleukin Basic information |
| Product Name: | Tucotuzumab Celmoleukin | | Synonyms: | Tucotuzumab Celmoleukin;Research Grade Tucotuzumab (DHD17404);Research Grade Tucotuzumab;Tucotuzumab (anti-EpCAM);Tucotuzumab | | CAS: | 339986-90-2 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Tucotuzumab Celmoleukin Structure]() |
| | Tucotuzumab Celmoleukin Chemical Properties |
| form | Liquid | | color | Colorless to light yellow |
| | Tucotuzumab Celmoleukin Usage And Synthesis |
| Uses | Tucotuzumab (Anti-EPCAM Recombinant Antibody) is an antigen-specific IgG1 monoclonal antibody that targets human epithelial cell adhesion molecule (EpCAM). Tucotuzumab links two IL-2 molecules and is an immunosuppressant and anti-tumor active molecule[1]. | | in vivo | Tucotuzumab (75 μg; intratumoral injection; 5 daily of 15 μg (total dose of 75 μg), each in 50 μL PBS; on days 10 and 14) results in significantly greater tumor growth suppression and enhances survival[1]. | Animal Model: | Female Balb/c mice bearing CT26-KS colon adenocarcinoma[1] | | Dosage: | 75 μg | | Administration: | Intratumoral injection; 5 daily of 15 μg (total dose of 75 μg), each in 50 μL PBS; on days 10 and 14 | | Result: | Resulted in significantly greater tumor growth suppression and enhanced survival.
|
| | References | [1] Erik E Johnson, et al. Radiofrequency ablation combined with KS-IL2 immunocytokine (EMD 273066) results in an enhanced antitumor effect against murine colon adenocarcinoma. Clin Cancer Res. 2009 Aug 1;15(15):4875-84. DOI:10.1158/1078-0432.CCR-09-0110 |
| | Tucotuzumab Celmoleukin Preparation Products And Raw materials |
|